Regeneron's Eylea could return to growth after nod to high-dose version- analysts
A quicker-than-expected U.S. approval for Regeneron Pharmaceuticals' high-dose eye disease drug, Eylea, should help return the blockbuster treatment back to growth in the next few years, Wall Stree...
Regeneron Pharmaceuticals shares rise on FDA approval of higher dose of eye disorder drug EYLEA
Regeneron Pharmaceuticals (NASDAQ:REGN) shares moved higher in pre-market trading after the biotechnology company reported on Friday that a higher dose of its eye disorder drug EYLEA has been appro...
Regeneron shares climb after FDA approval of macular degeneration treatment
Shares of Regeneron Pharmaceuticals Inc. REGN, +1.97% gained 1.4% premarket on Monday after the company said late Friday that the U.S. Food and Drug Administration had approved a higher-dose formul...
Is Regeneron Pharmaceuticals Still a Top Growth Stock?
Regeneron Pharmaceuticals has delivered market-beating results for shareholders over the prior 10 years. With competition heating up, however, the biotech may be entering a period of slowing growth.
Regeneron Gets Boost With FDA Approval Of High-Dose Eylea (Rating Upgrade)
Regeneron reported strong Q2 2023 financial results, with an 11% YoY revenue surge to $3.2B, outperforming expectations. The FDA approved high-dose Eylea (8 mg), offering less frequent treatment, a...
US FDA approves Regeneron's 8-mg dose of eye disease drug Eylea
The U.S. Food and Drug Administration approved the 8-mg dose of Regeneron Pharmaceuticals' eye disease drug Eylea, the company said in a statement on Friday.
Regeneron gets FDA green light on first treatment for life-threatening immune disease
Regeneron Pharmaceuticals Inc. REGN, +0.55% said Friday that the U.S. Food and Drug Administration has approved its treatment for CHAPLE disease, a rare and life-threatening hereditary immune disea...
Regeneron's (REGN) Application for Blood Cancer Drug Accepted
Regeneron's (REGN) application seeking approval of odronextamab for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma gets accepted for review in the EU.
Regeneron (REGN) to Buy Decibel, Gains on Hearing Loss Therapies
Regeneron (REGN) further builds upon its collaboration with Decibel by acquiring the company to expand its gene therapy programs for hearing loss.
Related Companies